Haploidentical Bone Marrow Transplantation in Sickle Cell Patients

This is a phase II, single arm, multi-center trial, designed to estimate the efficacy and toxicity of haploidentical bone marrow transplantion (BMT) in patients with sickle cell disease (SCD). Based on their age and entry criteria patients are stratified into two groups: (1) children with SCD with strokes; and (2) adults with severe SCD. Participants for this study will be for both males and females in the age range of 5 to 45 years old.

Phase I/II Study of Allogeneic Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

This trial is being conducted to test the safety and effectiveness of a stem cell transplant in the treatment of sickle cell disease patients as an alternative to Hydroxyurea therapy. Participants for this is for both males and females in the age range of 16-60 and must have a related matched donor.